Tristel

www.tristel.com TICKER: TSTL     EXCHANGE: AIM

Tristel develops proprietary infection, hygiene and contamination control products used by 1) Healthcare (branded Tristel); 2) Pharmaceutical and personal care (Crystel), and 3) Animal care (Anistel) organisations.

LATEST REPORTS

 
View the Results Webinar
Published: Feb 23 2017

You can now hear Paul Swinney, Chief Executive, and Liz Dixon, Finance Director, present the record interim results for the half year ended 31 December 2016 on behalf of Tristel plc.To view simply click on the video below. 

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Consistently strong growth at a sensible price
Published: Feb 23 2017

Tristel develops proprietary infection, hygiene and contamination control products used by organisations involved in: Human Healthcare (branded Tristel, 85% of sales);  Contamination Control (Crystel, 9%); and Animal care (Anistel. 6%).Instead of over-paying for unexciting behemoths, in today’s markets investors might think of  looking at  faster expanding small caps, trading at sensible valuations; like infection control expert, Tristel. Indeed, thanks to >95% of revenues being generated from everyday consumables, the company’s execution is almost metronomic - delivering

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Trading in-line with expectations
Published: Dec 13 2016

Tristel develops proprietary infection, hygiene and contamination control products used by: Human Healthcare (branded Tristel, 85% of sales); Contamination Control (Crystel, 9%), and Animal Care (Anistel. 6%) organisations. Its core chlorine dioxide chemistry is protected by 156 patents and deployed in c.400 UK hospitals.These days shareholder value is being built and protected by intellectual property, brands, networking benefits and such like. The big question for investors is naturally: 'what price to pay' for these type of high quality business? Tristel is a case in point. At 177p yesterda

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
View the Results Webinar
Published: Oct 20 2016

You can now hear Paul Swinney, Chief Executive, and Liz Dixon, Finance Director, present the preliminary results for Tristel plc (TSTL) and answer audience questions.To view simply click on the video below.

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Walking the talk
Published: Oct 17 2016

Tristel develops proprietary infection, hygiene and contamination control products used by: Human Healthcare (branded Tristel, 85% of sales); Contamination Control (Crystel, 9%); and Animal care (Anistel. 6%) organisations. For many years now management have communicated what they’re planning to do - and like clockwork successfully delivered against it, as illustrated again in this morning’s better than expected prelims for the year ending June 2016.FY16 turnover climbed 11.5% LFL to £17.1m (H1:H2 split 8.1%:14.8%), with 95% derived from every-day consumables and 39% from overseas territo

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Excellent H2 and ahead of forecasts
Published: Jul 21 2016

Tristel develops proprietary infection, hygiene and contamination control products used by organisations active in: Human Healthcare (branded Tristel, 84% of sales); Contamination Control (Crystel, 10%),; and Animal Care (Anistel. 6%). Despite fears over the global economy, NHS budgetary constraints and BREXIT, the company today  said that it had enjoyed a "very strong" 2nd half - reporting H2 revenues of >£9m, up 13.5% YoY. FY16 adjusted PBTA (pre SBP and unrealised forex gains) and net cash came in above expectations too, at £3.1m (+20% vs £2.6m LY) and £5.7m (vs ED at

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
View the Results Webinar
Published: Feb 26 2016

You can now hear Paul Swinney, Chief Executive, and Liz Dixon, Finance Director, present the interim results for Tristel plc (TSTL) and answer audience questions.To view simply click on the video below.

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

ARCHIVE

2016
Underlying H1 PBT jumps 35% to £1.5m
Published: Feb 23 2016

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2015
Plenty more left in the tank
Published: Dec 15 2015

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

View the Results Webinar
Published: Oct 14 2015

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

British innovator going global
Published: Oct 12 2015

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

And the news just gets better and better...
Published: Jun 18 2015

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Buoyant trading driving adj. PBTA up 39%
Published: May 21 2015

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

View the Interim Results Webinar
Published: Mar 01 2015

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Record sales with 15% like for like growth
Published: Feb 25 2015

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2014
PBT set to climb at least 38% in H1
Published: Dec 16 2014

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Tristel Preliminary Results Webinar, October 2014
Published: Oct 16 2014

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

All set for strong double-digit growth
Published: Oct 12 2014

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Reports 5th profit upgrade in past 12 months
Published: Jul 28 2014

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Tristel Investor Forum Presentation
Published: Jun 12 2014

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

FY14 PBT upgraded by 10%
Published: Jun 09 2014

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Material upgrades to forecast and price target
Published: Apr 27 2014

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Wiping out superbugs
Published: Mar 12 2014

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL